The effect of cinnamon supplementation on some blood biochemical parameters in Non-Insulin Dependent Type 2 Diabetes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138811133253N1

Enrollment

Registered

2010-04-15

Start date

2009-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Cinnamon supplementation, 1.5 gr daily, three capsules for 2 months. Intervention 2: weight flour supplementation, 1.5 gr daily, three capsoles for 2 months.

Treatment - Drugs

Placebo

Cinnamon supplementation, 1.5 gr daily, three capsules for 2 months

weight flour supplementation, 1.5 gr daily, three capsoles for 2 months

Eligibility

Sex/Gender

All

Age

1 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Consumption of anti hyperglycemic agents, not receiving any other drug, fasting blood glucose within the range of 140- 400mg/dl, moderate daily activity, Exclusion criteria: Pregnancy, consumption of Cinnamun, receiving insulin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood glucose. Timepoint: Baseline and at the end of trial. Method of measurement: Auto-analyzer.;Lipid profile. Timepoint: Baseline and at the end of trial. Method of measurement: Auto-analyzer.;Level of glycosylated hemoglobin. Timepoint: Baseline and at the end of trial. Method of measurement: HPLC.;Serum insulin level. Timepoint: Baseline and at the end of trial. Method of measurement: Chemoluminescense.;Insulin Resistance. Timepoint: Baseline and at the end of trial. Method of measurement: (Insulin*Glucose)/405.	—

Measure

Time frame

Blood glucose. Timepoint: Baseline and at the end of trial. Method of measurement: Auto-analyzer.;Lipid profile. Timepoint: Baseline and at the end of trial. Method of measurement: Auto-analyzer.;Level of glycosylated hemoglobin. Timepoint: Baseline and at the end of trial. Method of measurement: HPLC.;Serum insulin level. Timepoint: Baseline and at the end of trial. Method of measurement: Chemoluminescense.;Insulin Resistance. Timepoint: Baseline and at the end of trial. Method of measurement: (Insulin*Glucose)/405.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein khadem Haghighian

Tabriz University of Medical Sciences

khademnut@yahoo.com+98 41 1335 7580

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026